IP Library Granted Patent US 11,267,785
Granted Patent B2
US 11,267,785 · App. 16/921,273 · Granted Mar 8, 2022

Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Inventors: Christopher M. Lanthier (Burlington, CA); Boris Gorin (Oakville, CA); Jan Oudenes (Aurora, CA); Craig Edward Dixon (Brooklin, CA); Alan Quigbo Lu (Mississauga, CA); James Densmore Copp (Bargersville, IN); John Michael Janusz (Oregonia, OH)
Assignee: Akebia Therapeutics, Inc.
C07D213/81C07D213/79C07D213/803
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,267,785
App. No.
16/921,273
Granted
Mar 8, 2022
Kind
B2
Abstract

Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.

Claims (15)

1. A process for preparing compound (5):

comprising:

A. reacting (3-chlorophenyl)boronic acid:

with 3,5-dichloro-2-cyanopyridine:

in the presence of a catalyst and a base to form 5-(3-chlorophenyl)-3-chloro-2-cyanopyridine:

B. reacting 5-(3-chlorophenyl)-3-chloro-2-cyanopyridine with sodium methoxide to form 5-(3-chlorophenyl)-3-methoxy-2-cyanopyridine:

C. reacting 5-(3-chlorophenyl)-3-methoxy-2-cyanopyridine with hydrobromic acid or hydrochloric acid to form 5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxylic acid:

D. reacting 5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxylic acid with glycine methyl ester:

in the presence of a coupling reagent to form methyl {[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino}acetate:

and

E. reacting methyl {[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]amino}acetate with sodium hydroxide to form compound (5):

2. The process according to claim 1 , wherein the catalyst in step (A) is [1,1′-bis (diphenyphosphino)ferrocene]dichloro palladium(II).

3. The process of claim 1 , wherein the base of step (A) is LiOH, NaOH, KOH, Ca(OH) 2 , Li 2 CO 3 , Na 2 CO 3 , K 2 CO 3 , or CaCO 3 .

4. The process of claim 3 , wherein the base is K 2 CO 3 .

5. The process of claim 1 , wherein the acid of step (C) is hydrochloric acid.

Assignments (2)
SECURITY INTEREST Recorded Jan 29, 2024
From: AKEBIA THERAPEUTICS, INC.; KERYX BIOPHARMACEUTICALS, INC.
To: KREOS CAPITAL VII (UK) LIMITED
Reel/Frame 066377/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2021
From: LANTHIER, CHRISTOPHER M.; GORIN, BORIS; OUDENES, JAN; DIXON, CRAIG EDWARD; LU, ALAN QUIGBO; COPP, JAMES DENSMORE; JANUSZ, JOHN MICHAEL
To: AKEBIA THERAPEUTICS, INC.
Reel/Frame 055197/0079 →
Continuity (6)
Continuation 16352705 · Mar 13, 2019
Continuation 15692255 · Aug 31, 2017
Continuation 14833222 · Aug 24, 2015
Division 13488554 · Jun 5, 2012
Provisional Application 61493536 · Jun 6, 2011
Related Publication 20210122715A1 · Apr 29, 2021
Cited By (5)
US 12,478,615 US 12,569,474 US 12,612,367 US 12,629,357 US 12,673,919